Clinical trial · Interventional
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was closed to accrual according to the Fred Hutch/University of Washington/Seattle Children's Consortium low accrual institutional policy.
Summary
Brief summary (as posted)
This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic, alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and may also prevent community acquired respiratory virus infection in stem cell transplant recipients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematopoietic and Lymphoid Cell Neoplasm | Hematopoietic and Lymphoid Cell Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Solid Neoplasm | Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Best Practice | Other | — | UNRESOLVED |
| Nozin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (Nozin)
- description
- Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
- interventionNames
- Drug: Nozin
- type
- ACTIVE_COMPARATOR
- label
- Arm II (standard of care)
- description
- Patients receive standard of care.
- interventionNames
- Other: Best Practice
Primary outcomes (2)
- measure
- Tolerability of Nozin
- timeFrame
- Up to 100 days post-transplant
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease * English speaking * Capable of providing informed consent * Planned to receive follow-up at the transplant site for the first 100 days post transplantation * Subjects who the investigator believes can and will comply with the study protocol Exclusion Criteria: * Documented respiratory viral infection in the two weeks prior to enrollment * Current or planned use of any prophylactic antiviral therapy, antibody treatments, or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir, ribavirin, amantadine) * Known allergy to study drug components (jojoba, orange oil, coconut oil, lauric acid, benzalkonium chloride, vitamin E) * Receiving oxygen supplementation at time of enrollment * Active mucositis at time of enrollment * Ongoing irritation or active infection of the squamous epithelial cell skin involving the nose or nasal vestibule * Daily use of nasal decontamination products or other nasal medications (e.g. nasal steroids) * Unable to complete study procedures (e.g. nasal swab self-testing)
References
Publications (0)
Data not yet available